BioRestorative Therapies, Inc.
General ticker "BRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $9.5M (TTM average)
BioRestorative Therapies, Inc. does not follow the US Stock Market performance with the rate: -19.5%.
Estimated limits based on current volatility of 6.9%: low 1.36$, high 1.56$
Factors to consider:
- Total employees count: 13 (+18.2%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Going concern doubt, Financing risks, Clinical trial delays, Regulatory and compliance, Product development failure
- Current price 85.2% below estimated low
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.44$, 34.15$]
- 2026-12-31 to 2027-12-31 estimated range: [5.75$, 20.22$]
Financial Metrics affecting the BRTX estimates:
- Positive: with PPE of -0.7 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 85.71 > 2.08
- Positive: Interest expense per share per price, % of 0 <= 0
- Negative: negative Operating cash flow
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 7.04 < Shareholder equity ratio, % of 8.74 <= 12.78
Short-term BRTX quotes
Long-term BRTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.15MM | $0.40MM | $0.36MM |
| Operating Expenses | $15.37MM | $11.96MM | $16.01MM |
| Operating Income | $-15.22MM | $-11.56MM | $-15.65MM |
| Non-Operating Income | $4.80MM | $2.58MM | $1.41MM |
| R&D Expense | $4.03MM | $5.35MM | $10.09MM |
| Income(Loss) | $-10.42MM | $-8.98MM | $-14.24MM |
| Net Income(Loss)* | $-10.42MM | $-8.98MM | $-14.24MM |
| Stockholders Equity | $10.00MM | $8.53MM | $0.36MM |
| Assets | $12.61MM | $12.28MM | $4.08MM |
| Operating Cash Flow | $-6.43MM | $-8.23MM | $-10.79MM |
| Capital expenditure | $0.17MM | $0.11MM | $0.12MM |
| Investing Cash Flow | $3.25MM | $0.51MM | $8.90MM |
| Financing Cash Flow | $2.35MM | $7.38MM | $2.85MM |
| Earnings Per Share** | $-49.39 | $-23.13 | $-31.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.